Background: Ewing sarcoma family of tumors (ESFT) of the kidney are exceedingly rare. Given the rarity of this neoplasm and the complexity associated with its management, information regarding treatment and outcome is warranted.
R enal cell carcinoma (RCC) is the most common type of kidney cancer accounting for 80% to 85% of all cases. RCC primarily arises from the renal cortex with the clear cell subtype being the most common. Although other malignant tumors such as transitional cell carcinoma of the renal pelvis, and collecting duct carcinoma are well known, extraosseous neuroectodermal neoplasms including Ewing sarcoma family of tumors (ESFT) arising in the kidney present diagnostic and therapeutic challenges, given the rarity of these tumors.
Renal ESFT are aggressive tumors and often difficult to differentiate clinically and radiologically from RCC and transitional cell carcinoma of the renal pelvis and hence are frequently misdiagnosed. ESFT includes Ewing sarcoma, primitive neuroectodermal tumor (PNET), and Askin tumor. They are small round cell tumors that typically arise in bone, soft tissue, and chest wall. ESFT of genitourinary tract are rare and were first described by Seemayer et al 1 and tend to occur most often in young adults. These tumors are characterized by t(11;22) (q24;q12), EWS-FLI-1 fusion gene, which is integral to the diagnosis. 2 Renal ESFT can be pathologically confused with other small round cell tumors arising from the kidney, such as small cell carcinoma, Wilm tumor, monophasic synovial sarcoma, and lymphoma. Given the rarity of this diagnosis and the complexity associated with management of these tumors, information regarding treatment modalities and outcome of patients with renal ESFT is limited thus prompting our retrospective study. Herein, we present a case series of adult patients with renal ESFT who were treated at our institution and summarize the clinical characteristics, treatment modalities, and outcomes.
PATIENTS AND METHODS
Following Institutional Review Board approval, a retrospective study of the clinical and pathologic records of adult patients seen and treated at MDACC from January 1, 2001 to January 1, 2011 was conducted. The pathologic specimens were reviewed by a dedicated sarcoma pathologist. All cases of confirmed ESFT were included in this review, and nonrenal cell cancers (carcinoid tumors of kidney and small cell carcinoma of kidney) were excluded. Radiographic studies were reviewed with particular attention to the presence of tumor thrombus in major vessels. Overall survival (OS) was determined from diagnosis to death secondary to ESFT as well as other causes. Data collected at baseline included demographics (age, race, sex), past medical history, prognostic variables, nephrectomy, systemic therapy with treatment data (ie, initiation and discontinuation dates of therapy), last available date of follow-up or date of death.
RESULTS
Thirteen cases with renal ESFT were identified including 1 case which we previously reported 3 now with further follow-up information. There were 11 males and 2 females. The median age at diagnosis was 33 years (range, 31 to 45 y). Eight patients were nonsmokers. The most common presenting symptoms were back pain/flank pain (53.8%), abdominal pain (23%), and hematuria (23%); 1 patient presented with left testicular swelling and 2 other patients presented with abdominal mass. Two of the 13 patients were anemic at diagnosis but 1 of these 2 patients had an underlying chronic kidney disease. The tumor size ranged from 7 to 16.2 cm. The radiologic appearance of a renal mass extending into the renal vessels similar to RCC was noted in 65% of our cases. The tumor was more frequently seen arising from the left kidney, although no particular site predominance has been reported in the literature. The radiologic appearance of the renal mass had no specific characteristics to distinguish it from RCC, except where the tumor was noted to arise from renal hilum or was central/medullary in nature which is atypical for RCC. The presence of extensive metastases and atypical appearance of renal mass prompted a biopsy instead of upfront nephrectomy in 6 cases. Five of the 13 cases were noted to have a tumor thrombus in the major vessels.
On review of the pathology, the gross appearance of tumor was noted to vary from tan-yellow to grayish-white with areas of necrosis and hemorrhage in 3 cases. Twelve cases were described as small round blue cell tumor with abundant round cells and minimal cytoplasm. The immunohistochemical profile showed strong positivity for CD99 in 11 of 13 patients. Tumors were negative for chromogranin, synaptophysin, WF-1, desmin, and vimentin. Cytogenetic analysis for EWSR1 transcript was performed in 10 of 13 cases and 8 of them were noted to be positive for EWSR1(q22;q12) gene rearrangement. Two cases were negative for the EWSR1 gene rearrangement; however, the morphology in conjunction with the immunohistochemical profile (strong and diffuse CD99 reactivity) were thought to be consistent with ESFT, and hence these patients were categorized as renal ESFT. Table 1 summarizes the demographic, radiographic, clinical, and immunohistochemical features of the 13 cases.
Six patients had metastases at initial presentation. The most common sites of metastases were the retroperitoneum and lungs. All 6 patients underwent a diagnostic biopsy initially, and 5 of them received upfront systemic chemotherapy consisting of the combination of VAI (vincristine, doxorubicin, ifosfamide) alternating with the EP regimen (cisplatin-etoposide). 4, 5 Two of these 6 patients with metastases at presentation underwent nephrectomy: one had presurgical chemotherapy followed by cytoreductive nephrectomy, whereas the other patient who had disease limited to kidney and the ipsilateral adrenal gland underwent upfront left radical nephrectomy with left adrenalectomy followed by adjuvant chemotherapy.
The remaining 7 patients who did not have metastases at presentation underwent nephrectomy and were diagnosed with renal ESFT histologically following the nephrectomy. All of these 7 patients received adjuvant chemotherapy consisting mostly of VAI alternating with EP with irinotecan used as a salvage agent after relapse. The median number of systemic chemotherapy regimens administered was 2 (range, 1 to 5) and the median total time on systemic chemotherapy was 11.2 months (range, 3.5 to 29.8 mo). Table 2 summarizes the treatment modalities including nephrectomy, systemic chemotherapy, and the outcome of each of the 13 patients.
Ten of the 13 patients have died and the OS was 17.2 months (range, 6.5 to 112.8 mo). One patient who presented with metastatic disease in July 2003 3 and received chemotherapy only is alive with no evidence of disease, whereas the other patient who underwent nephrectomy followed by adjuvant chemotherapy is alive with no evidence of disease 2 years since diagnosis.
DISCUSSION
Neuroectodermal tumors of the kidney, although rare, are a distinct clinicopathologic entity and are poorly differentiated round cell tumors traditionally defined by their primitive neural features such as rosette formation at the light microscopic level and secretory granule formation at the ultrastructural level. 6 ESFT arises from bone in >80% of cases, especially in children, and arises less frequently from extraskeletal sites. 7 ESFT of bone is the second most common primary bone malignancy occurring in the flat and long bones, and presents with localized pain and swelling. Extraskeletal ESFT occurs more commonly in young adults, compared with skeletal Ewing, which tends to occur in young children and adolescents. The most common site of extraskeletal ESFT is the trunk. Tumors in this location tend to have an insidious onset, and a delayed diagnosis; and are frequently large at presentation. 8 ESFT has a propensity for the kidney and retroperitoneum. Originating from the cells of primitive neuroectoderm, renal ESFT may be the result of embryonic neural crest cells migrating into the kidneys thereby undergoing tumorigenesis. Approximately 75% of renal ESFTs tend to occur in young adults similar to our case series. Of note, our study population included adult patients only (age range, 31 to 45 y), whereas the Zöllner et al 9 review included pediatric and adult patients (age range, 11 to 59.8 y). Immunoreactivity for CD99 (mic2) 10 is present in the vast majority of ESFT, as was noted in our series (11 of 13 patients in our series were positive for CD99). Molecularly, ESFT is characterized by translocations and fusions of the EWSR1 gene with a number of the ETS family of genes. EWSR1-ETS fusion protein is believed to be pivotal to the tumorigenesis of ESFT and the tumor phenotype. 11 The most frequent translocation is t(11;22) (q24;12) which results from fusion of the 5 0 end of the EWSR1 to the 3 0 of FLI-1 and accounts for >85% of all translocations. Molecular confirmation of gene rearrangement is widely considered to be integral to the diagnosis of ESFT as the immunohistochemical and histologic features of ESFT overlap with other small round blue cell tumors that may occur in the kidney, such as desmoplastic small blue round cell tumor and synovial sarcoma. Although helpful for the diagnosis, the absence of EWSR1 gene rearrangement does not entirely exclude the diagnosis of ESFT, especially if the clinical and morphologic features are highly suggestive of the diagnosis. In our series, cytogenetic analysis was performed in 10 of 13 cases and 8 of them demonstrated the presence of EWSR1 fusion gene rearrangement.
The presence of a vascular tumor thrombus has been cited as a distinctive feature of renal ESFT/PNET, and was noted in 56.2% of the cases reported by Zöllner and colleagues as compared with 38.4% in our study and has been linked to a higher rate of pulmonary metastases, although our patients showed equal predilection for lung metastases regardless of the presence of a tumor thrombus. Six (46%) of our patients had an initial diagnostic biopsy performed, as compared with 33.3% in a recent literature review. 12 We believe many patients with renal ESFT do not undergo initial biopsy before nephrectomy, due to similar presentation to RCC, thereby precluding the delivery of upfront systemic chemotherapy. The standard treatment of nonmetastatic renal ESFT has been widely accepted as nephrectomy with neoadjuvant and adjuvant chemotherapy. 13 However, chemotherapy alone may be sufficient to produce long-term survival in patients with metastatic disease, with durable complete remissions and potential cure in a few patients, as we previously reported. 3 The majority of patients (94.1%) in the Zöllner and colleagues' review received local therapy with surgery or radiotherapy, or both, with 37.5% of patients having metastatic disease at diagnosis. In contrast, only 69% of patients in our series underwent surgery and no patients received radiation, with 46.1% of patients having metastatic disease at presentation. This highlights the importance of chemotherapy and no local therapy in the treatment of metastatic ESFT. Subclinical metastatic disease is present in 80% to 90% of ESFT of the bone, with overt metastases occurring in <25% of cases; however, renal ESFT tends to present with overt metastases more frequently 14 as we noted in our series. In a large series of 182 patients with ESFT/PNET, the 5-year OS rate was reported to be 41%, and the median OS for patients without metastatic disease was 61 months as compared with 14 months for patients with metastatic disease at presentation. 15 Another study 16 
CONCLUSIONS
ESFTs of the kidney are exceedingly rare and can be clinically confused with RCC and may show histologic overlap with other small round cell tumors. Ancillary studies including immunohistochemistry play an important role in differentiating them from other tumors. Our case series emphasizes the importance of performing a diagnostic biopsy in atypical renal masses, before nephrectomy, especially in patients with metastatic disease. An important goal is to avoid unnecessary surgery, as nephrectomy would delay and may even preclude the delivery of effective systemic chemotherapy, such as highdose ifosfamide. Our data highlight the effective role of chemotherapy in achieving durable complete remission and potential cure without the need for nephrectomy in a few patients with ESFT even if they have metastatic disease. However, novel more effective therapies for ESFT are still needed. 
